文献速递甲状腺疾病

甲状腺功能减退症患者的治疗偏好

Treatment Preferences in Patients With Hypothyroidism.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

系统评价、Meta分析、Meta回归和网状Meta分析比较成人甲减患者对左甲状腺素(L-T4)单药与L-T4+碘塞罗宁(L-T3)或干燥甲状腺提取物(DTE)的偏好,纳入11项随机对照试验共1135例患者,24%偏好L-T4,52%偏好联合治疗或DTE,24%无偏好;Meta分析证实联合治疗偏好优于单药(RR 2.20,95%CI 1.38-3.52,P=.0009)。

要点

  • 甲减患者中52%偏好联合治疗或DTE,24%偏好L-T4单药,24%无偏好。
  • Meta分析显示联合治疗偏好优于L-T4单药(RR 2.20,95%CI 1.38-3.52,P=.0009)。
  • 网状Meta分析证实对DTE和L-T3+L-T4的偏好优于L-T4单药。

核心结论

  • 甲状腺功能减退症患者偏好联合治疗(L-T3+L-T4或DTE)而非L-T4单药治疗,这些发现的强度支持在甲减治疗的共享决策中考虑患者偏好。

研究设计与样本

  • 系统评价、Meta分析、Meta回归和网状Meta分析,纳入比较成人甲减治疗(L-T4 vs L-T4+L-T3或DTE)的随机对照试验(RCT),检索PubMed、Embase和Cochrane数据库至2024年4月10日,由4名研究者独立提取数据和评估质量,共纳入11项RCT(8项交叉研究)1135例患者。

主要发现

  • 总体24%患者偏好L-T4,52%偏好L-T4+L-T3或DTE,24%无偏好。
  • Meta分析证实联合治疗偏好优于L-T4单药(RR 2.20,95%CI 1.38-3.52,P=.0009)。
  • 排除4项研究后异质性由I²=81%降低,结果不受影响(RR 1.97,95%CI 1.52-2.54,P<.00001,I²=24%)。
  • 仅考虑交叉研究时偏好特征不变(RR 2.84,95%CI 1.50-5.39,P<.00001)。
  • 网状Meta分析证实对DTE和L-T3+L-T4的偏好优于L-T4单药。

临床怎么用

  • 作者认为这些发现的强度支持在甲减治疗的共享决策中考虑患者偏好。

局限性

  • 排除4项研究前异质性高(I²=81%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Levothyroxine (L-T4) monotherapy is the standard of care for the treatment of hypothyroidism. A minority of L-T4-treated patients remain symptomatic and report better outcomes with combination therapy that contains liothyronine (L-T3) or with desiccated thyroid extract (DTE). OBJECTIVE: This work aimed to assess patient preferences in the treatment of hypothyroidism. METHODS: A systematic review, meta-analysis, meta-regression, and network meta-analysis of randomized controlled trials (RCTs) comparing treatments for adults with hypothyroidism (L-T4 vs L-T4 + L-T3 or DTE). Searches were conducted in PubMed, Embase, and Cochrane databases up to April 10, 2024. Data extraction and quality assessment were independently performed by 4 researchers. RESULTS: Eleven RCTs (8 cross-over studies) with a total of 1135 patients were considered. Overall, 24% of patients preferred L-T4 vs 52% who preferred L-T4 + L-T3 or DTE; 24% had no preference. The meta-analysis confirmed the preference for combination therapy over L-T4 monotherapy (relative risk [RR]: 2.20; 95% CI, 1.38-3.52; P = .0009). Excluding 4 studies reduced the high heterogeneity (I2 = 81%) without affecting the results (RR: 1.97; 95% CI, 1.52-2.54; P < .00001; I2 = 24%). This preference profile remained when only crossover studies were considered (RR: 2.84; 95% CI, 1.50-5.39; P < .00001). Network meta-analysis confirmed the preference for DTE and L-T3 + L-T4 vs L-T4 alone. CONCLUSION: Patients with hypothyroidism prefer combination therapy (L-T3 + L-T4 or DTE) over L-T4 monotherapy. The strength of these findings justifies considering patient preferences in the setting of shared decision-making in the treatment of hypothyroidism.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. de Lima Beltrão FE, Carvalhal G, de Almeida Beltrão DC, et al. Treatment Preferences in Patients With Hypothyroidism. J Clin Endocrinol Metab. 2025. PMID: 39290156. doi:10.1210/clinem/dgae651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。